Navigation Links
Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection
Date:8/5/2009

SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin hydrochloride injection. IMS data indicates the combined U.S. market for these two products approximated $25 million in 2008. Sagent will begin marketing and shipping both products immediately.

"We are very pleased to begin expanding our product line to include vital oncology products," said Jeffrey M. Yordon, chief executive officer, founder and chairman of the board of Sagent. "Our epirubicin and fludarabine products are each latex and preservative free, and bear Sagent's hallmark packaging, designed to help healthcare providers quickly and accurately identify the right product and dose."

Fludarabine for injection, USP will be offered in 50 mg single-use vials. Epirubicin hydrochloride injection will be offered in 50 mg per 25 mL and 200 mg per 100 mL single-dose vials.

About Fludarabine Phosphate for Injection, USP

Fludarabine phosphate for injection, USP (generic equivalent to Fludara(R), distributed by Bayer HealthCare Pharmaceuticals) is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of the product in previously untreated or non-refractory patients with CLL have not been established.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.

About Epirubicin Hydrochloride Injection

Epirubicin hydrochloride injection (generic equivalent to Ellence(R), distributed by Pfizer Oncology) is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
3. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
4. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
5. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
6. Sagent Pharmaceuticals Announces Extension of Series A Financing
7. Sagent Pharmaceuticals Enters Into a $15 Million Revolving Credit Facility
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Women's Excellence ... Roberta Jordan is a Certified Nurse Midwife who was born and raised in ... went on to complete her masters degree from the University of Mexico. Roberta ...
(Date:5/24/2016)... California (PRWEB) , ... May ... ... a nationwide provider of communication enabled solutions and managed services today announced ... software for the enterprise contact center market. , Altura, one of Avaya’s ...
(Date:5/24/2016)... ... ... New Jersey: This year marks Children’s Specialized Hospital ’s 125th anniversary of helping ... hospital has themed the milestone “Hats Off” and kicked off the yearlong celebration at ... 21, at Johnson Park in Piscataway, New Jersey. , “Hats Off” is ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has officially broken ... Children’s Hospital. Over 3,000 people looked on as the shovels hit the dirt at ... slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report ... on their access to trusted resources, both in face-to-face interactions and online. In “Heard, ... Color,” researchers concluded that the creative use of mobile digital devices can be an ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 Clarifying ... Diagnostics and Monitoring, and Vision Care What ... areas are going to grow at the fastest rates? ... to 2026, assessing data, trends, opportunities and prospects. ... and graphs. Discover the most lucrative areas in the ...
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/20/2016)... May 20, 2016 ReportsnReports.com ... to Medical Devices of its online business intelligence ... on the current state of the Titrator industry. ... industry like definitions, classifications, Specifications, applications and industry ... process like Raw Material Suppliers, Equipment Suppliers, Manufacturing ...
Breaking Medicine Technology: